About PeploBio

Prior to founding PeploBio, Phoebe was a co-founder of Serametrix, a California-based CRO, where she led the Commercial-Operations efforts to develop and commericalise novel assays for measuring immunity in cancer patients.

Prior to founding PeploBio, Henry was a co-founder of Serametrix, a California-based CRO, where he worked to develop and commericalise novel assays for measuring immunity in cancer patients. His work has included the successful launch of several flow cytometry assays for measuring peripheral cells – assays that have been widely used in the clinical development of novel immune-oncology drugs such as PD-1 inhibitors. The MDSC monitoring assay (CLIA) is now used to help select patients for clinical trial. Other assays include T Effector Memory Cells and peripheral activated dendritic cells (DC-LAMP). Prior to PeploBio, Henry worked to establish a US-based office for a British start-up biotech, sales rep for Becton Dickinson and as a postdoc researching mad cow / prion diseases.

A co-founder of PeploBio, Dr. Lambri has over 12 years of experience in academic and clinical research, laboratory operations and commercial strategy. Having established a rapidly growing molecular diagnostics laboratory, PeploBio is an industry leader in immunoassays, genomics, immune monitoring, metabolomics, and personalised medicine. With strategic partnerships formed in both the pharmaceutical and biotechnology sector, PeploBio develops proprietary diagnostics in the fields of oncology, neurodegenerative, metabolic, and infectious diseases. Dr. Lambri’s expertise includes assay development and validation using a variety of platforms (immunoassay, flow cytometry, mass spectrometry, qPCR, and others) for biomarker analysis. Having validated numerous assays, Dr. Lambri is experienced with overseeing their deployment including both exploratory and primary endpoints, technical aspects and regulatory requirements (ISO 15189 and CLIA).
Dr. Lambri is committed to advancing Precision Medicine and establishing productive partnerships across the biopharmaceutical sector.‍

Mohammed joined PeploBio as a Quality Consultant and was appointed Chief Operating Officer in February 2022. He has over 7 years’ experience in the NHS where he was the HCPC registered Chief Biomedical Scientist and site manager for the Microbiology Service. His operational expertise enabled service delivery to over 6 hospitals and their surrounding healthcare practices, processing in excess of 220,000 samples per annum. As an IBMS examiner for the Specialist Diploma, his interests lie in the fields of bacteriology, virology, parasitology and mycology. His practical knowledge spans across a number of manual and automated methods including immunoassays, molecular PCR, microscopy and culture techniques. Possessing post-graduate qualifications in Quality Systems Management and Governance and Risk Management, he is well versed in the regulatory requirements of obtaining ISO 15189 accreditation and HSE approved status for CL3 facilities. Mohammed is committed to making timely and effective testing services more accessible to patients through the use of rapidly evolving technologies.

John Corliss has more than 20 years of experience, including 15 years in the life science research tools and diagnostics industry. John has significant experience in large and small companies across sales, commercial operations, service delivery, and global supply chain operations. Most recently, he served as VP of Global Service & Sales Operations of Standard BioTools. Previously, he contributed to the rapid organic and inorganic growth of the genomics business of Agilent Technologies through roles in corporate development and operations finance. He holds a BA in Economics from the University of Chicago and an MBA from the Wharton School. John is based in Chapel Hill, North Carolina.

Loryn joined PeploBio as Laboratory Director and was recently appointed Principal Scientist in December 2022. Dr Halliday’s broad research experience spans the fields of oncology, microbiology, immunology and pharmacology. This has allowed her to develop novel proprietary assays (molecular, immunoassays, flow cytometry). She played a key role in gaining UKAS accreditation to ISO 15189 and provides scientific consultancy and management of clinical evaluation studies. She also regularly trains, supervises, and mentors scientific personnel. Her research expertise originated within oncology observing epigenic modifications (Acute myeloid leukaemia), to viral oncology (HPV) and, later, paediatric autoinflammatory disorders. Dr. Halliday is committed to the translation of basic to clinical research and bringing innovation to precision medicine.